#United States #Palo Alto #Evommune #EVO756 #Chronic Urticaria

Evommune's Groundbreaking Presentation at EADV 2025

Evommune, Inc., a prominent biotechnology firm specializing in innovative therapies for chronic inflammatory diseases, has announced a major milestone in its research efforts. The company will present the full data from its Phase 2 clinical trial of EVO756 at the European Academy of Dermatology and Venereology Congress (EADV) scheduled to take place in Paris from September 17-20, 2025. This late-breaker oral presentation will spotlight the effectiveness of EVO756 in treating chronic inducible urticaria (CIndU).

EVO756 is a novel oral small molecule that specifically targets the mas-related G-protein coupled receptor X2 (MRGPRX2). By modulating both mast cells and peripheral sensory neurons, this promising therapy aims to provide significant improvements in managing chronic inflammatory conditions, particularly CIndU. Currently, EVO756 is undergoing further evaluation in Phase 2b trials assessing its efficacy for Chronic Spontaneous Urticaria and Atopic Dermatitis, with hopes for a broader application in neuroinflammatory disorders.

Details of the Presentation

The details of the presentation at EADV are as follows:

• - Abstract N° LBA-260: EVO756, an Oral MRGPRX2 Inhibitor, Demonstrates Robust Treatment Effect in Chronic Inducible Urticaria
• - Date and Time: September 19, from 2:30 PM to 2:45 PM CEST (8:30 AM to 8:45 AM EST)
• - Session Title: D3T01.3B
• - Location: Paris Nord

During this session, Dr. Edward (Ted) Lain, a board-certified dermatologist and investigator, alongside Evommune's management team, will host a webcast to discuss the critical findings from the trial. The webcast link will be live on the company’s website, coinciding with the press release and presentation on September 19 at 8:30 AM EST.

The Unmet Need in Chronic Urticaria

Chronic inducible urticaria, a condition characterized by recurrent hives triggered by various stimuli, significantly impacts the quality of life for those afflicted. The current treatment landscape leaves much to be desired, with many patients experiencing inadequate relief. Evommune targets this unmet need, aiming to provide a first-in-class oral therapy that enhances treatment effectiveness while ensuring patient safety and convenience in administration.

By innovatively targeting MRGPRX2, EVO756 marks a significant shift in therapeutic strategies, representing what could be a dual mechanism approach in treating these conditions. It aims at not only alleviating itch (pruritus) swiftly but also reducing overall inflammation.

About Evommune

Evommune is dedicated to advancing therapies that tackle chronic inflammation, striving to enhance patients' daily lives and mitigate the long-term repercussions of unmanaged inflammatory responses. Through a robust pipeline that includes the cutting-edge EVO756, Evommune aims to address significant gaps in the treatment landscape for chronic urticaria, atopic dermatitis, and potentially neuroinflammation in the future. For additional information, interested parties are encouraged to visit www.evommune.com or connect with them on LinkedIn.

As the EADV Congress approaches, anticipation builds around EVO756's promising clinical data and its potential ramifications in the realm of chronic inflammatory diseases. The presentation and subsequent discussion will spotlight not only the innovations in therapy but also Evommune's commitment to advancing patient care in chronic conditions.